Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891524 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,242
- Enrollment target
NCT03891524 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,242 participants.
The verdict
NCT03891524, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,242 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.
Interventions
- DRUG Placebo
- DRUG JNJ-70033093 25 mg
- DRUG JNJ-70033093 50 mg
- DRUG JNJ-70033093 100 mg
- DRUG JNJ-70033093 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,242 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891524
The ClinicalTrials.gov registry entry for NCT03891524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03891524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03891524 about?
NCT03891524 is a clinical study titled "A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery". The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[...
What is the current status of trial NCT03891524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,242 participants. The study started on 2019-06-17. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT03891524?
The interventions under investigation include: Placebo (DRUG), JNJ-70033093 25 mg (DRUG), JNJ-70033093 50 mg (DRUG), JNJ-70033093 100 mg (DRUG), JNJ-70033093 200 mg (DRUG).
Who is sponsoring clinical trial NCT03891524?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.